Accordingly, MMJ announces that its unaudited NTA per share as at 31 December 2018 was 22.48 cents (pre-tax) and 21.16 cents (post-tax)*.
MMJ's investment portfolio (as at 12 January 2019) is summarised as follows: (see link below)
MMJ's CEO Jason Conroy commented that "A strong rebound over the past few weeks in the share prices of our public company investments (Harvest One and MediPharm Labs) has increased our post-tax NTA to approximately 27 cents per share as at 12 January 2019. We are very pleased with this improving performance and look forward to announcing further progress and developments across our portfolio in the coming months."
* The pre and post-tax numbers relate to the provision for deferred tax on the unrealised gains in MMJ's investment portfolio. Under current Accounting Standards, MMJ is required to provide for tax on any gains that may arise on such a theoretical disposal, after the utilisation of brought forward losses.
To view tables, please visit:
About MMJ Group Holdings Ltd
MMJ Group Holdings Ltd (ASX:MMJ) is a global cannabis investment company. MMJ owns a portfolio of minority investments and aims to invest across the full range of emerging cannabis-related sectors including healthcare, technology, infrastructure, logistics, processing, cultivation, equipment and retail. For MMJ's latest investor presentation and news, please visit: http://www.mmjphytotech.com.au/investors/
ContactInvestor and Media Enquiries:
Chief Executive Officer
MMJ Group Holdings Ltd (ASX:MMJ) MediPharm Labs (CVE:LABS) Ships over CAD$10m of Cannabis Oil in December 2018
MMJ Group Holdings Ltd (ASX:MMJ) MediPharm Labs (CVE:LABS) Replenishes Cannabis Inventory to Meet Demand